Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
Martin Hutchings(University of Copenhagen), Michael Dickinson(The University of Melbourne), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Carmelo Carlo‐Stella(Humanitas University), Franck Morschhauser(Hôpital Claude Huriez), Emmanuel Bachy(Université Claude Bernard Lyon 1), D. Callejo(Roche (Switzerland)), Michael Crump(University of Toronto), Linda Lundberg(Roche (Switzerland)), Mark Dixon(Roche (United Kingdom)), James Relf(Roche (United Kingdom)), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), David Carlile(Roche (Switzerland)), Kathryn Humphrey(Roche (United Kingdom)), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Fritz Offner(Ghent University Hospital), Emily Piccione(California Institute for Regenerative Medicine)
Cited by 56
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907